Hypnotic and sedative drugs - Anything new on the horizon?
Publication in refereed journal


香港中文大学研究人员 ( 现职)

Professor Tony GIN (麻醉及深切治疗学系)

全文

数位物件识别号 (DOI) http://dx.doi.org/10.1097/ACO.0b013e328362a7a3

引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/6WOS source URL
Scopushttp://aims.cuhk.edu.hk/converis/portal/Publication/6Scopus source URL

其它资讯

摘要PURPOSE OF REVIEW: Many studies of new intravenous sedative drugs have been published last year, including several phase I trials. This review provides a brief summary of these studies, with recommendations for selected reading. RECENT FINDINGS: Remimazolam is a rapidly metabolized benzodiazepine. Early clinical trials confirm more rapid recovery compared with midazolam. Etomidate analogues can be designed with rapid metabolism and without adrenocortical suppression, but research is only at the preclinical stage. MR04A3 and AZD3043 are gamma-aminobutyric acid A agonists with phase I data, but the outlook for further development is uncertain. Pioneers of intravenous emulsions of volatile anesthetics continue their work. SUMMARY: Many of the new sedative drugs were designed to undergo rapid metabolism. Remimazolam has great potential to enter clinical practice because of its rapid offset of action. ? 2013 Lippincott Williams & Wilkins.

着者Gin T.
期刊名称Current Opinion in Anaesthesiology
出版年份2013
月份8
日期1
卷号2http://aims.cuhk.edu.hk/converis/portal/Publication/6
期次4
出版社Lippincott Williams & Wilkins Ltd.
出版地United States
页次409 - 413
国际标準期刊号0952-7907
电子国际标準期刊号1473-http://aims.cuhk.edu.hk/converis/portal/Publication/6500
语言英式英语

关键词etomidate, remimazolam, sedatives, soft drugs